ACP
PRAX icon

Acuta Capital Partners’s Praxis Precision Medicines PRAX Stock Holding History

Acuta Capital Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7M Sell
82,796
-2,105
-2% -$666K 19.32% 1
2026
Q1 		$27.4M Buy
84,901
+1,865
+2% +$577K 19.3% 1
2025
Q4 		$24.5M Buy
83,036
+33,285
+67% +$6.2M 16.62% 2
2025
Q3 		$2.64M Sell
49,751
-24,336
-33% -$1.18M 2.72% 12
2025
Q2 		$3.12M Sell
74,087
-13,054
-15% -$497K 4.35% 9
2025
Q1 		$3.3M Buy
87,141
+19,641
+29% +$1.23M 3.83% 10
2024
Q4 		$5.19M Buy
67,500
+10,000
+17% +$724K 5.23% 7
2024
Q3 		$3.31M Sell
57,500
-106,931
-65% -$5.78M 2.68% 15
2024
Q2 		$6.8M Buy
164,431
+2,129
+1% +$101K 5.73% 5
2024
Q1 		$9.9M Sell
162,302
-137,334
-46% -$6.16M 6.43% 2
2023
Q4 		$6.68M Buy
299,636
+636
+0.2% +$11.5K 3.76% 8
2023
Q3 		$7.67M Buy
299,000
+15,667
+6% +$296K 5.14% 4
2023
Q2 		$4.89M Buy
+283,333
New +$4.34M 3.31% 12
2021
Q2 		– Sell
-10,282
Closed -$5.05M – 47
2021
Q1 		$5.05M Buy
10,282
+5,239
+104% +$3.73M 1.82% 25
2020
Q4 		$4.16M Buy
+5,043
New +$2.94M 1.13% 32

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Acuta Capital Partners's PRAX Position: Q2 2026 in Review

Acuta Capital Partners reduced its Praxis Precision Medicines (PRAX) stake by 2.5% in Q2 2026, selling an estimated $666K and leaving 82,796 shares worth $27.7M. The position accounts for 19.32% of the portfolio, ranked #1.

Acuta Capital Partners first reported a position in PRAX in Q4 2020 and has held it in 15 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Acuta Capital Partners held 82,796 shares of Praxis Precision Medicines worth $27.7M as of Q2 2026.
  • Acuta Capital Partners sold 2,105 Praxis Precision Medicines shares in Q2 2026, an estimated $666K.
  • Praxis Precision Medicines made up 19.32% of Acuta Capital Partners's portfolio in Q2 2026, its #1 holding.
  • Acuta Capital Partners first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 15 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.